Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis
Copyright © 2021 Elsevier B.V. All rights reserved..
OBJECTIVE: We aimed to investigate serum glial fibrillary acidic protein (GFAP) and serum neurofilament light chain (NfL) levels as potential discriminative biomarkers between benign relapsing-remitting multiple sclerosis (BRRMS) and aggressive relapsing-remitting MS (ARRMS).
METHODS: Serum GFAP and NfL levels were analyzed in patients with BRRMS (n = 34), ARRMS (n = 29), and healthy controls (n = 14) by using Single Molecule Array (Simoa). Patients with ARRMS had been treated with highly effective disease-modifying treatments (DMT) (fingolimod or natalizumab).
RESULTS: Serum GFAP levels in both BRRMS (median 210.19 pg/ml, IQR 163.69-287.19) and in ARRMS (median 188.60 pg/ml, IQR39.23-244.93) were significantly higher (p = 0.035 and p = 0.034, respectively) compared to healthy controls (median 117.93 pg/ml, IQR 60.28-183.83). Serum GFAP levels did not differ between BRRMS and ARRMS. There were no statistical differences in NfL levels between BRRMS, ARRMS and healthy controls. GFAP level was significantly higher (p = 0.04) in BRRMS without DMT (median 216.04 pg/ml, IQR 188.60-274.79) than in those BRRMS patients who had used DMT (median 196.26 pg/ml, IQR 133.33-325.54).
CONCLUSIONS: We found elevated levels of serum GFAP in both BRRMS and ARRMS compared to healthy controls, reflecting astrocytic activation. Serum NfL did not differ between BRRMS and ARRMS, probably due to the stable inflammatory phase of the disease and effective DMT use in ARRMS. Single serum NfL and GFAP measurements cannot separate a patient with BRRMS from effectively treated ARRMS after a long history of the disease, thus consecutive samples are needed in the follow-up.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Multiple sclerosis and related disorders - 56(2021) vom: 26. Nov., Seite 103280 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Niiranen, Marja [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.12.2021 Date Revised 31.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.msard.2021.103280 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331679515 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331679515 | ||
| 003 | DE-627 | ||
| 005 | 20231225214006.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.msard.2021.103280 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM331679515 | ||
| 035 | |a (NLM)34627002 | ||
| 035 | |a (PII)S2211-0348(21)00547-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Niiranen, Marja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2021 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier B.V. All rights reserved. | ||
| 520 | |a OBJECTIVE: We aimed to investigate serum glial fibrillary acidic protein (GFAP) and serum neurofilament light chain (NfL) levels as potential discriminative biomarkers between benign relapsing-remitting multiple sclerosis (BRRMS) and aggressive relapsing-remitting MS (ARRMS) | ||
| 520 | |a METHODS: Serum GFAP and NfL levels were analyzed in patients with BRRMS (n = 34), ARRMS (n = 29), and healthy controls (n = 14) by using Single Molecule Array (Simoa). Patients with ARRMS had been treated with highly effective disease-modifying treatments (DMT) (fingolimod or natalizumab) | ||
| 520 | |a RESULTS: Serum GFAP levels in both BRRMS (median 210.19 pg/ml, IQR 163.69-287.19) and in ARRMS (median 188.60 pg/ml, IQR39.23-244.93) were significantly higher (p = 0.035 and p = 0.034, respectively) compared to healthy controls (median 117.93 pg/ml, IQR 60.28-183.83). Serum GFAP levels did not differ between BRRMS and ARRMS. There were no statistical differences in NfL levels between BRRMS, ARRMS and healthy controls. GFAP level was significantly higher (p = 0.04) in BRRMS without DMT (median 216.04 pg/ml, IQR 188.60-274.79) than in those BRRMS patients who had used DMT (median 196.26 pg/ml, IQR 133.33-325.54) | ||
| 520 | |a CONCLUSIONS: We found elevated levels of serum GFAP in both BRRMS and ARRMS compared to healthy controls, reflecting astrocytic activation. Serum NfL did not differ between BRRMS and ARRMS, probably due to the stable inflammatory phase of the disease and effective DMT use in ARRMS. Single serum NfL and GFAP measurements cannot separate a patient with BRRMS from effectively treated ARRMS after a long history of the disease, thus consecutive samples are needed in the follow-up | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Benign multiple sclerosis | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a GFAP | |
| 650 | 4 | |a Multiple sclerosis | |
| 650 | 4 | |a Neurofilament | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Glial Fibrillary Acidic Protein |2 NLM | |
| 650 | 7 | |a Natalizumab |2 NLM | |
| 650 | 7 | |a Neurofilament Proteins |2 NLM | |
| 650 | 7 | |a neurofilament protein L |2 NLM | |
| 650 | 7 | |a Fingolimod Hydrochloride |2 NLM | |
| 650 | 7 | |a G926EC510T |2 NLM | |
| 700 | 1 | |a Kontkanen, Aleksi |e verfasserin |4 aut | |
| 700 | 1 | |a Jääskeläinen, Olli |e verfasserin |4 aut | |
| 700 | 1 | |a Tertsunen, Hanna-Mari |e verfasserin |4 aut | |
| 700 | 1 | |a Selander, Tuomas |e verfasserin |4 aut | |
| 700 | 1 | |a Hartikainen, Päivi |e verfasserin |4 aut | |
| 700 | 1 | |a Huber, Nadine |e verfasserin |4 aut | |
| 700 | 1 | |a Solje, Eino |e verfasserin |4 aut | |
| 700 | 1 | |a Haapasalo, Annakaisa |e verfasserin |4 aut | |
| 700 | 1 | |a Kokkola, Tarja |e verfasserin |4 aut | |
| 700 | 1 | |a Lohioja, Tarja |e verfasserin |4 aut | |
| 700 | 1 | |a Herukka, Sanna-Kaisa |e verfasserin |4 aut | |
| 700 | 1 | |a Simula, Sakari |e verfasserin |4 aut | |
| 700 | 1 | |a Remes, Anne M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Multiple sclerosis and related disorders |d 2012 |g 56(2021) vom: 26. Nov., Seite 103280 |w (DE-627)NLM219118388 |x 2211-0356 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2021 |g day:26 |g month:11 |g pages:103280 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.msard.2021.103280 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2021 |b 26 |c 11 |h 103280 | ||